Showcase

公司名稱 Company Name

華港龍生物科技有限公司
Greater Bay Biotechnology Limited

公司網站 Company Website 

公司簡介 Company Background
華港龍生物科技是HK Tech 300支持的企業,專注於創新AI+生物藥物及細胞透皮遞送科技的研發與轉化,包括用於治療糖尿病、肥胖症的胰島素和多肽冰凍微針科技,在香港、深圳、上海都有醫療健康業務。華港龍將於港深創科園設立研發和轉化中心,與有關部門、大學、醫療機構、投資機構等夥伴合作轉化
Greater Bay Biotechnology (GBBT) focuses on the R&D and commercialization of AI-enabled transdermal drug and cell delivery technology, including its patented cryomicroneedle technology. The company plans to establish its R&D hub in HSITP to advance clinical translation, generate real-world evidence (RWE), and develop solutions that can be adopted within Hong Kong’s healthcare system. It also aims to support cross-border healthcare integration and accelerate research-to-clinic commercialization in Chinese Mainland and internationally.
陳列產品之簡介 Description of displayed product
本公司陳列之產品為冷凍微針無痛給藥系統。這是一個創新的藥物遞送平台,專為胰島素、GLP-1、mRNA 及活細胞等的儲存、輸送與經皮給藥而設計。相較打針,此技術提供了一種微創且無痛的替代方案,同時有助於降低糖尿病患者低血糖風險和胰島素抵抗, 提升患者的治療依從性。
The displayed product is our AI-enabled cryomicroneedle painless drug delivery system. It is an innovative drug-device combination platform designed for the storage, transport, and transdermal delivery of insulin, GLP-1, proteins, peptides, mRNA, and living cells. Compared with conventional delivery approaches, the technology offers a minimally invasive and pain free alternative, while helping preserve the activity of sensitive biologics, lower the risk of and insulin resistence. The CMN technology is intended to improve patient compliance, with application in diabetes, obesity.treatment.
公司產品 Company products